



Deposited via The University of Sheffield.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/158807/>

Version: Accepted Version

---

**Article:**

Jin, H., Tappenden, P., Robinson, S. et al. (2020) A systematic review of economic models across the entire schizophrenia pathway. *PharmacoEconomics*, 38 (6). pp. 537-555. ISSN: 1170-7690

<https://doi.org/10.1007/s40273-020-00895-6>

---

This is a post-peer-review, pre-copyedit version of an article published in *PharmacoEconomics*. The final authenticated version is available online at: <http://dx.doi.org/10.1007/s40273-020-00895-6>.

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

1 **A systematic review of economic models across the entire schizophrenia pathway**

2 **1. Title of paper**

3 **Full title:** A systematic review of economic models across the entire schizophrenia pathway

4 **Running title:** Review of economic models for schizophrenia

5 **2. Journal Name:** PharmacoEconomics

6 **3. List of authors**

<b>Name</b>	<b>Preferred degree</b>	<b>Affiliation</b>	<b>Contact details</b>	<b>ORCID ID</b>
Huajie Jin <i>(Corresponding author)</i>	PhD	King's Health Economics (KHE), Institute of Psychiatry, Psychology & Neuroscience at King's College London, London, UK.	<b>Email:</b> <a href="mailto:huajie.jin@kcl.ac.uk">huajie.jin@kcl.ac.uk</a> <b>Telephone:</b> +44 (0)20 7848 0878 <b>Address:</b> King's Health Economics Institute of Psychiatry, Psychology & Neuroscience at King's College London Box 024, The David Goldberg Centre, London, UK, SE5 8AF	0000-0002-3872-3998
Paul Tappenden	PhD	Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Sheffield, UK.	<b>Address:</b> HEDS, ScHARR University of Sheffield Regent Court, 30 Regent Street Sheffield, UK, S1 4DA	0000-0001-6612-2332
Stewart Robinson	PhD	School of Business and Economics, Loughborough University, Loughborough, UK.	<b>Address:</b> School of Business and Economics Loughborough University Epinal Way Loughborough Leicestershire, UK, LE11 3TU	0000-0002-6016-0167

<b>Name</b>	<b>Preferred degree</b>	<b>Affiliation</b>	<b>Contact details</b>	<b>ORCID ID</b>
Evanthia Achilla	MSc	IQVIA, Singapore.	<b>Address:</b> IQVIA, 79 Anson Road, #19-01, Singapore, 079906	0000-0002-7402-2769
James H MacCabe	FRCPsych	The Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience at King's College London, London, UK.	<b>Address:</b> The Department of Psychosis Studies, PO63 Institute of Psychiatry, Psychology & Neuroscience at King's College London London, UK, SE5 8AF	0000-0002-6754-1018
David Aceituno	MD	King's Health Economics (KHE), Institute of Psychiatry, Psychology & Neuroscience at King's College London, London, UK.	<b>Address:</b> King's Health Economics Institute of Psychiatry, Psychology & Neuroscience at King's College London Box 024, The David Goldberg Centre, London, UK, SE5 8AF	0000-0002-2967-5816
Sarah Byford	PhD	King's Health Economics (KHE), Institute of Psychiatry, Psychology & Neuroscience at King's College London, London, UK.	<b>Address:</b> King's Health Economics Institute of Psychiatry, Psychology & Neuroscience at King's College London Box 024, The David Goldberg Centre, London, UK, SE5 8AF	0000-0001-7084-1495

1

2

1 **Abstract**

2 **Background:** Schizophrenia is associated with a high economic burden. Economic models can help to inform  
3 resource allocation decisions to maximise benefits to patients.

4 **Objectives:** This systematic review aims to assess the availability, quality and consistency of conclusions of  
5 health economic models evaluating the cost-effectiveness of interventions for schizophrenia.

6 **Methods:** An electronic search was performed on multiple databases (MEDLINE, EMBASE, PsycInfo,  
7 Cochrane database of systematic reviews, NHS Economic Evaluation Database and Health Technology  
8 Assessment database) to identify economic models of interventions for schizophrenia published between 2005-  
9 2020. Two independent reviewers selected studies for inclusion. Study quality was assessed using the National  
10 Institute for Health and Care Excellence (NICE) checklist and the Cooper hierarchy. Model characteristics and  
11 conclusions were descriptively summarised.

12 **Results:** Seventy-three models met inclusion criteria. 78% of existing models assessed antipsychotics, however,  
13 due to inconsistent conclusions reported by different studies, no antipsychotic can be considered clearly cost-  
14 effective compared with the others. A very limited number of models suggest that the following non-  
15 pharmacological interventions might be cost-effective: psychosocial interventions, stratified tests, employment  
16 intervention and intensive intervention to improve liaison between primary and secondary care. The quality of  
17 included models is generally low due to use of a short time horizon, omission of adverse events of interventions,  
18 poor data quality and potential conflicts of interest.

19 **Conclusions:** This review highlights a lack of models for non-pharmacological interventions, and limitations of  
20 the existing models, including low quality and inconsistency in conclusions. Recommendations on future  
21 modelling approaches for schizophrenia are provided.

22

1 **Key Points for Decision Makers**

- 2 • This is the first systematic review of model-based economic analyses which covers the entire  
3 schizophrenia care pathway, by including any intervention for the prevention, detection, diagnosis,  
4 treatment and follow-up of schizophrenia.
- 5 • This review highlights a lack of models for non-pharmacological interventions, and low quality of  
6 existing models. Common reasons for low-quality include use of a time-horizon which is not  
7 sufficiently long, failure to capture the health and cost impact of adverse events of the interventions  
8 under assessment, and potential conflicts of interest.
- 9 • Due to inconsistent conclusions reported by different studies, no antipsychotic can be considered  
10 clearly cost-effective compared with the others. A very limited number of models suggest that the  
11 following non-pharmacological interventions might be cost-effective: psychosocial interventions,  
12 stratified tests, employment intervention and intensive intervention to improve liaison between primary  
13 and secondary care.
- 14 • A consistent basis for the model structure, use of evidence and assumptions in health economic models  
15 is required in order to improve the consistency and quality of future health economic models in  
16 schizophrenia. This consistent basis could be applied using generic agreed models, which might  
17 include a de novo whole disease model.

18

19 **Declaration of interests & acknowledgments**

20 No funding was received for this review. JM received grants from HS Lundbeck outside this submitted review.

21 HJ, PT, SR, EA, DA and SB declare no conflicts of interest.

22

# 1                    **A systematic review of economic models across the entire schizophrenia pathway**

## 2   **1. Introduction**

3   Schizophrenia is a chronic, severe and disabling psychiatric disorder, or cluster of disorders, characterised by  
4   psychotic symptoms that alter a person’s perceptions, thoughts, affect and behaviour. The schizophrenia clinical  
5   guideline developed by the National Institute for Health and Care Excellence (NICE) recommends a wide range  
6   of interventions for people who are at risk of, or who have a diagnosis of, schizophrenia, including  
7   antipsychotics, cognitive behaviour therapy (CBT), family intervention, peer support, physical health checks  
8   and interventions, and education and employment support [1]. However, the rates of implementation are low for  
9   some recommended interventions including physical health interventions (13%), family interventions (31%),  
10   CBT (41%) and supported employment programmes (63%) [2]. It has been reported that the allocations for  
11   mental health care in national health budgets are commonly disproportionate to the burden of mental health  
12   conditions in many countries [3]. For example, in the UK, although mental disorders are responsible for 28% of  
13   the total burden of disease, mental health care only receives 13% of total NHS funding [4]. As a result, mental  
14   health commissioners may not be in a position to fund all recommended interventions and must decide how to  
15   allocate limited budgets across the entire care pathway in a way that maximises benefits to patients.

16  
17   Since clinical trials rarely collect all of the information required to estimate the full profiles of health outcomes  
18   and costs for all interventions relevant to a decision problem, health economic modelling is routinely used to  
19   simulate the current and proposed systems of care, with input data obtained from multiple sources [5]. The  
20   purpose of this review is to conduct a systematic review of existing health economic models of any type for  
21   schizophrenia and provide recommendations for future research. Specific objectives were as follows:

- 22        (1) To assess the availability of economic models of interventions for patients who are at risk of, or who  
23            have a diagnosis of schizophrenia;
- 24        (2) To critically examine the quality of existing health economic models;
- 25        (3) To summarise the conclusions reported by existing health economic models and to assess the  
26            consistency of conclusions.

## 27 28   **2 Methods**

29   This systematic review was conducted according to the PRISMA recommendations for reporting systematic  
30   reviews and meta-analyses of studies that evaluate healthcare interventions [6].

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30

## **2.1 Inclusion/exclusion criteria**

Inclusion and exclusion criteria were defined *a priori*. Studies were included if they met all of the following criteria: (i) studies reporting model-based economic evaluations adopting either a cost-effectiveness analysis (CEA) or cost-utility analysis (CUA) approach; (ii) focus on young people (under 18 years of age) and/or adults (18 years and older) who are at clinical high risk of psychosis (CHR), with a non-specific diagnosis of psychosis, or with a diagnosis of schizophrenia (including schizoaffective disorder and delusional disorder), and (iii) interventions targeted at the prevention, detection, diagnosis, treatment or follow-up of schizophrenia. No restrictions by country, health care setting or monetary currency were applied. Studies were excluded if they met any of the following criteria: (i) reviews, commentaries, letters, editorials, or abstracts; (ii) published before 2005, or (iii) not reported in English.

## **2.2 Search strategy**

Electronic biomedical and psychological databases searched included MEDLINE (including in-Process & other non-indexed), EMBASE and PsycINFO, accessed through the Ovid interface (<https://ovidsp.ovid.com/>). In addition, the NHS Economic Evaluation Database (NHSEED) and the Health Technology Assessment Database (HTA) were searched, accessed through the Cochrane library interface (<http://onlinelibrary.wiley.com/cochranelibrary/search8>). The search strategies included Medical Subject Heading (MeSH) terms and text words. Each follows a similar structure: population terms AND economic evaluation terms AND modelling terms AND limitation terms. The original search, first update search and second update search were conducted on 22<sup>nd</sup> June 2015, 4<sup>th</sup> March 2018, and 21<sup>st</sup> January 2020), respectively. The detailed search strategy is reported in Online Resource 1, Section 1. Retrieved search results were downloaded into Endnote X8.0.2.

## **2.3 Assessment of abstracts for inclusion**

Screening of abstracts and papers against the inclusion criteria was carried out by two reviewers (HJ and EA for the original and first update search; HJ and DA for the second update search). Final inclusion of studies in the review was determined by agreement of both reviewers, with disagreements resolved by discussion. A number of additional strategies were devised to help ensure that relevant studies were not missed. Firstly, key papers and the publications of key health economists were checked for inclusion and for additional relevant papers.

1 Secondly, published systematic reviews relevant to the target population were located through a separate search  
2 of NICE clinical guidelines, NICE technology appraisals and National Institute for Health Research (NIHR)  
3 health technology assessment (HTA) reports. The search terms used by the located systematic reviews were  
4 used to inform the development of search strategies for the current systematic review, and the studies included  
5 within those reviews were checked for relevance with respect to the inclusion criteria of the current systematic  
6 review. Finally, the reference lists of all included studies identified via the electronic search were checked for  
7 any additional studies that may have been missed by the electronic search strategies.

8

#### 9 **2.4 Data extraction and analysis**

10 Data were extracted by one reviewer (HJ) and checked by a second reviewer (EA for the original and first  
11 update search, DA for the second update search), with disagreements resolved by discussion. The following  
12 information was extracted from all included studies: author; year; country; study objective; type of economic  
13 evaluation; intervention and comparator; modelling method; willingness-to-pay threshold (e.g. per quality-  
14 adjusted life year [QALY] gained), conclusions, potential conflicts of interest and information on quality criteria  
15 set out by the NICE checklist and Cooper hierarchy. Study characteristics and conclusions were summarised  
16 descriptively.

17

#### 18 **2.5 Quality assessment**

19 Seven commonly used checklists for economic evaluations [7-13] were considered for the current review, they  
20 differ from each other in terms of the aim of the quality assessment (e.g. to assess reporting quality, or  
21 methodological quality of economic evaluations, or both) and the types of studies covered (e.g. trial-based  
22 economic evaluations, model-based economic evaluations, or both). To be of value to the current review,  
23 checklists needed to (i) focus on methodological quality of studies; (2) be appropriate for modelling studies; and  
24 (3) provides an overall judgement regarding the methodological quality of the studies assessed, so to help the  
25 reviewers to summarise and compare the methodological quality of a large number of included studies (e.g.  $\geq 50$   
26 studies). Based on these three criteria, two checklists were deemed to be most appropriate for the current review:  
27 Section 2 of the NICE checklist [11] and the Cooper hierarchy [10]. The NICE checklist consists of two  
28 sections. Section 1 aims to assess the applicability of a study to the decision problems that need to be addressed  
29 by the NICE guidance, for example, whether the study population is appropriate to the review question of  
30 interest or whether the system in which the study was conducted is sufficiently similar to the current UK

1 context. As the aim of this systematic review was to provide an overview of the availability and quality of all  
2 economic models focusing on the schizophrenia care pathway, Section 1 was not considered relevant. Section 2  
3 of the NICE checklist aims to assess the methodological quality of the study and thus was included. Section 2  
4 consists of twelve quality criteria and an overall assessment. Based on the number and importance of quality  
5 criteria that a study fails, an assessment regarding the overall methodological quality of the study can be  
6 classified into one of the following categories: (i) very serious limitations – the study fails to meet one or more  
7 quality criteria, and this is highly likely to change the conclusions about cost effectiveness, (ii) potentially  
8 serious limitations – the study fails to meet one or more quality criteria, and this could change the conclusions  
9 about cost effectiveness, and (iii) minor limitations – the study meets all quality criteria, or fails to meet one or  
10 more quality criteria but this is unlikely to change the conclusions about cost effectiveness, potentially serious  
11 limitations and minor limitations. The Cooper hierarchy focuses on the quality of the data sources used to  
12 inform the parameters in a model [10]. The hierarchy provides a list of potential sources for each data  
13 component of interest, including: main clinical effect size, baseline clinical data, adverse events and  
14 complications, resource use, costs and utilities. Sources are ranked on a scale from 1 to 6, with the most  
15 appropriate source assigned a rank of 1. Where multiple data inputs were included within a category (i.e.  
16 adverse events and complications, resource use and cost), the score of the worst sources of evidence were  
17 recorded. Based on the value of the score, the quality of input data was then categorised as high ranked evidence  
18 (score 1-2), medium ranked evidence (score 3-4) or low ranked evidence (score 5-6). The Cochrane Handbook  
19 for Systematic Reviews [14] recommends the Cooper hierarchy as a useful supplement to more comprehensive  
20 checklists such as the NICE checklist.

21

## 22 **3 Results**

### 23 **3.1 Study identification and selection**

24 A total of 1,557 citations were retrieved from electronic searches carried out on three separate occasions  
25 (original search 22<sup>nd</sup> June 2015; first update d search 4<sup>th</sup> March 2018, second update search 21<sup>st</sup> January 2020).  
26 The detailed results of the literature search are reported in Online Resource 1, Section 1. Four modelling studies  
27 known to one of the authors (HJ), but which was not identified by the electronic searches was added to the  
28 database. These four studies were reported in the adult NICE schizophrenia guideline [1], and were missed by  
29 the electronic searches because NICE clinical guidelines are not currently indexed by mainstream electronic  
30 databases. After removing duplicates, 1,250 citations remained: 908 citations identified from the original

1 electronic searches, 204 identified from the first updated electronic searches, 134 identified from the second  
2 updated electronic searches, plus the four models identified from the NICE schizophrenia guideline for adults  
3 [1]. Of the 1,250 abstracts reviewed, 981 were excluded for clearly failing to meet at least one inclusion  
4 criterion or meeting at least one exclusion criterion, leaving 269 for full-text review. Of these, 97 were abstracts  
5 only and for the remaining 172, full articles were retrieved. Of these, 77 papers reporting 73 studies (four papers  
6 are corrections of other included studies) satisfied the predefined inclusion criteria and were included in the  
7 review. The inter-reviewer agreement, measured by Cohen's kappa was 0.84, which indicates good agreement.  
8 A modified preferred reporting items for systematic reviews and meta-analyses (PRISMA) diagram [6] for the  
9 literature selection process is provided in Fig. 1. The key data extracted from included studies are reported in the  
10 Online Resource 1, Section 2.

11

### 12 **3.2 Study descriptions**

13 Table 1 summarises the characteristics of included studies. 89.0% of included studies (65/73) were from high-  
14 income countries, such as the US (11/73, 15.1%), the UK (11/73, 15.1%) and Sweden (6/73, 8.2%). Fifty-eight  
15 included studies were CUAs (79.5%), while fifteen were CEAs (20.5%). The perspective of cost adopted by  
16 included studies are healthcare system (36/73, 49.3%), third-party payer (22/73, 30.1%), healthcare system and  
17 social care (8/73, 11.0%) and society (7/73, 9.6%). The majority of studies adopted a time horizon from one to  
18 five years (52/73, 71.2%). The most commonly used modelling techniques were Markov model (34/73, 46.6%),  
19 decision tree (24/73, 32.9%) and discrete event simulation (DES) (9/73, 12.3%). In terms of population, the  
20 majority of included studies related to people with a diagnosis of schizophrenia (68/73, 93.2%). The remaining  
21 studies evaluated interventions for people with a non-specific diagnosis of psychosis (5/73, 6.8%) [1, 15-18] and  
22 those at CHR (2/73, 2.7%) [15, 17]. In terms of interventions assessed, most included studies compared the cost-  
23 effectiveness of different antipsychotics versus each other, placebo or nothing (57/73, 78.1%). The remaining  
24 studies assessed the cost-effectiveness of different coverage of Medicare drug plans (1/53, 1.6%) [19],  
25 electroconvulsive therapy (ECT) versus antipsychotic (1/53, 1.6%) [20], precision medicine test versus no test  
26 (4/73, 5.5%) [21-24], different monitoring schedules for patients receiving clozapine (1/73, 1.4%) [25],  
27 antipsychotics versus antipsychotics plus psychosocial interventions (5/73, 6.8%) [26-30], CBT versus no CBT  
28 (1/73, 1.4%) [17], improving patients' access to psychological therapies versus no intervention (1/73, 1.4%)  
29 [18], supported employment programme vs no intervention (1/73, 1.4%) [1], and different modes of liaison  
30 between primary and secondary care services (1/53, 1.6%) [15]. The availability of economic evidence across

1 the schizophrenia care pathway is presented in Fig. 2. As shown in Fig. 2, there is high availability of economic  
2 evidence for antipsychotic with or without psychosocial interventions and moderate availability of economic  
3 evidence for prevision medicine test. On the other hand, there is very limited or even no economic evidence  
4 concerning the prevention, case identification, assessment and diagnosis of psychosis and schizophrenia, as well  
5 as non-pharmacological interventions for people with a diagnosis of psychosis or schizophrenia.

6

7

**Table 1 Characteristics of included studies**

	<b>Included studies (n=73)</b>
	n (%)
<b>Country</b>	
High-income countries	65 (89.0)
Low- and middle-income countries	8 (11.0)
<b>Type of economic evaluation</b>	
Cost-utility analysis	58 (79.5)
Cost-effectiveness analysis excluding cost-utility analysis	15 (20.5)
<b>Perspective of cost</b>	
Healthcare system	36 (49.3)
Third-party payer	22 (30.1)
Healthcare system and social care	8 (11.0)
Society	7 (9.6)
<b>Time horizon</b>	
<1 year	2 (2.7)
1-5 year	52 (71.2)
10-year	6 (8.2)
Lifetime	13 (17.8)
<b>Modelling techniques adopted</b>	
Markov model	34 (46.6)
Decision tree	24 (32.9)
DES	9 (12.3)
Microsimulation	5 (6.8)
Not reported	1 (1.4)
<b>Target population</b>	
People at clinical high risk of psychosis	2 <sup>1</sup> (2.7)
People with a non-specific diagnosis of psychosis	5 <sup>1</sup> (6.8)
People with a diagnosis of schizophrenia	68 (93.2)
<b>Interventions assessed</b>	
Antipsychotic medication versus each other, placebo or nothing	57 (78.1)
Different coverage of Medicare drug plans	1 (1.4)
Electroconvulsive therapy versus antipsychotic medication	1 (1.4)

	<b>Included studies (n=73)</b>
	n (%)
Precision medicine test versus no test	4 (5.5)
Different monitoring schedule for patients on clozapine	1 (1.4)
Antipsychotic medication versus antipsychotic medication plus psychosocial interventions	5 (6.8)
CBT versus no CBT	1 (1.4)
Improving patients' access to psychological therapies	1 (1.4)
Supported employment programme	1 (1.4)
Different modes of liaison between primary and secondary care service	1 (1.4)

1 **Notes:**

2 1: Two studies [15, 17] included two groups of people: people at CHR and people with non-specific diagnosis of psychosis.

3

4 **3.3 Quality assessment**

5 The results of the quality assessment are reported below; further detail is provided in Online Resource 1, Section  
6 3.

7

8 *3.3.1 NICE checklist*

9 According to the quality assessment results of the NICE checklist, sixty-two studies were deemed to have very  
10 serious limitations (84.9%), eight were deemed to have potentially serious limitations (11.0%), and three were  
11 deemed to have minor limitations (4.1%) [1, 17, 31]. The performance of included studies on all items of the  
12 NICE checklist is shown in Fig. 3. Common problems identified for all included studies are: (1) potential  
13 conflict of interest (58/73, 79.5%); (2) use of time horizon not sufficiently long to reflect all important outcomes  
14 (54/73, 74.0%); and (3) baseline outcome data not obtained from the best available source: (49/73, 67.1%). Of  
15 the sixty-two studies deemed to have very serious limitations, the most common reasons for them to be assessed  
16 as very serious limitations are (some studies can be assessed as very serious limitations for more than one  
17 reasons): (1) did not include all important and relevant costs, for example, the cost of treating adverse events of  
18 antipsychotics (42/62, 67.7%); (2) failure to include all important and relevant outcomes, for example, disutility  
19 caused by adverse events of antipsychotics (40/62, 64.5%); and (3) the model structure did not adequately  
20 reflect the nature of the topic under evaluation (26/62, 41.9%), for example, did not model discontinuation of  
21 antipsychotics due to intolerability or non-adherence.

22

1 *3.3.2 Cooper hierarchy*

2 Fig. 4 presents the results of applying the Cooper hierarchy to the included studies. Of the six categories  
3 included in the Cooper hierarchy, three of them (adverse events, resources use and costs) may include multiple  
4 data inputs (i.e. more than one data source can be used for that category). For these three categories, the score of  
5 the lowest quality evidence were reported. As shown in Fig. 4, most studies used high-ranked evidence for unit  
6 costs (49/73, 67.1%) and clinical treatment effects (47/73, 64.4%), and low-ranked evidence for baseline clinical  
7 events (49/73, 67.1%), resource use (47/73, 64.4%) and adverse events (30/73, 41.1%). Of the fifty-eight CUA  
8 studies which modelled patients' utilities, most used medium-ranked evidence to inform utility estimates (54/58,  
9 93.1%).

10

11 **3.4 Results of existing models**

12 The cost-effectiveness conclusions of exiting models are summarised in Table 2.

**Table 2 Summary of included studies by decision questions assessed**

Target population	Number of studies	Countries	Study quality	Summary of results	Conclusion
<b><i>1. Different antipsychotics versus each other, placebo or nothing</i></b>					
<b>Schizophrenia patients in an acute episode</b>	10	UK (2/10,20.0%) [16, 32], Czech Republic (1/10,10.0%) [33], Germany (1/10,10.0%) [34], Greece (1/10,10.0%) [35], Mexico (1/10,10.0%) [36], Norway (1/10,10.0%) [37], Spain (1/10,10.0%) [38], Sweden (1/10,10.0%) [39], and US (1/10,10.0%) [40]	Very serious limitations (10/10, 100.0%)	The most cost-effective antipsychotic reported by included studies are: <ul style="list-style-type: none"> <li>• Oral paliperidone extended release (3/10, 30.0%) [33, 35, 38];</li> <li>• Oral olanzapine (2/10, 20.0%) [34, 37];</li> <li>• Oral lurasidone (1/10,10.0%) [32];</li> <li>• Oral sertindole (1/10,10.0%) [39];</li> <li>• Oral ziprasidone (1/10,10.0%) [36];</li> <li>• Oral risperidone (1/10,10.0%) [40];</li> <li>• Oral atypical (1/10,10.0%) [16].</li> </ul>	No antipsychotic can be considered clearly cost effective compared with the other options.
<b>Schizophrenia patients in remission</b>	12	US (4/12, 33.3%) [41-44], Spain (2/12, 16.7%) [45, 46], Brazil (1/12, 8.3%) [47], China (1/12,	Very serious limitations (7/12, 58.3%), potentially serious limitations (3/12,	The most cost-effective antipsychotic reported by included studies are: <ul style="list-style-type: none"> <li>• Oral olanzapine (3/12, 25.0%) [31, 41, 43];</li> </ul>	No antipsychotic can be considered clearly cost effective compared with the other options.

Target population	Number of studies	Countries	Study quality	Summary of results	Conclusion
		8.3%) [48], Singapore (1/12, 8.3%) [31], Thailand (1/12, 8.3%) [49], Uganda (1/12, 8.3%) [50] and UK (1/12, 8.3%) [1].	25.0%) [41, 42, 49], and minor limitations (2/12, 16.7%) [1, 31].	<ul style="list-style-type: none"> <li>• Oral risperidone (2/12, 16.7%) [47, 50];</li> <li>• Oral ziprasidone (2/12, 16.7%) [42, 45];</li> <li>• Oral aripiprazole (1/12, 8.3%) [49];</li> <li>• Olanzapine orally disintegrating tablet (1/12, 8.3%) [48];</li> <li>• Oral brexpiprazole (1/12, 8.3%) [44];</li> <li>• Oral paliperidone extended release (1/12, 8.3%) [46];</li> <li>• Oral zotepine (1/12, 8.3%) [1].</li> </ul>	
<b>General schizophrenia patients (psychotic status unspecified)</b>	5	Canada (2/5, 40.0%) [51, 52], Australia (1/5, 20.0%) [53], Germany (1/5, 20.0%) [54] and Sweden (1/5, 20.0%) [55]	Very serious limitations (5/5, 100.0%) [51-55]	<p>The most cost-effective antipsychotic reported by included studies are:</p> <ul style="list-style-type: none"> <li>• Oral aripiprazole (1/5, 20.0%) [55];</li> <li>• Oral asenapine (1/5, 20.0%) [51];</li> <li>• Oral branded risperidone (1/5, 20.0%) [54];</li> <li>• Oral risperidone (1/5, 20.0%) [52];</li> </ul>	No antipsychotic can be considered clearly cost effective compared with the other options.

Target population	Number of studies	Countries	Study quality	Summary of results	Conclusion
				<ul style="list-style-type: none"> <li>Low-dose oral typical (1/5, 20.0%) [53].</li> </ul>	
<b>Schizophrenia patients who have history of non-adherence</b>	24	Finland (2/24, 8.3%) [56, 57], Germany (2/24, 8.3%) [58, 59], Portugal (2/24, 8.3%) [60, 61], Sweden (2/24, 8.3%) [62, 63], US (2/24, 8.3%) [64, 65], Belgium (1/24, 4.2%) [66], Canada (1/24, 4.2%) [67], China (1/24, 4.2%) [68], Croatia (1/24, 4.2%) [69], Czech Republic (1/24, 4.2%) [70], France (1/24, 4.2%) [71], Greece (1/24, 4.2%) [72], Netherlands (1/24,	Very serious limitations (23/24, 95.8%) and potentially serious limitations (1/24, 4.2%) [78]	<p>The most cost-effective antipsychotic reported by included studies are:</p> <ul style="list-style-type: none"> <li>Paliperdione LAI (11/24, 45.8%) [56, 57, 60, 62, 69-74, 79];</li> <li>Risperidone LAI (7/24, 29.2%) [58, 61, 63, 66-68, 77];</li> <li>Aripiprazole LAI (2/24, 8.3%) [64, 78];</li> <li>Olanzapine LAI (2/24, 8.3%) [65, 76];</li> <li>Oral atypical (1/24, 4.2%) [59];</li> <li>Oral olanzapine (1/24, 4.2%) [75].</li> </ul>	No antipsychotic can be considered clearly cost effective compared with the other options.

Target population	Number of studies	Countries	Study quality	Summary of results	Conclusion
		4.2%) [73], Norway (1/24, 4.2%) [74], Slovenia (1/24, 4.2%) [75], Spain (1/24, 4.2%) [76], Taiwan (1/24, 4.2%) [77], UK (1/24, 4.2%) [78], and United Arab Emirates (1/24, 4.2%) [79].			
<b>Patients with treatment-resistant schizophrenia (TRS)</b>	3	Australia (1/3, 33.3%) [53], South Korea (1/3, 33.3%) [80] and UK (1/3, 33.3%) [20]	Very serious limitations (2/3, 66.7%) [53, 80] and potentially serious limitations (1/3, 33.3%) [20]	The Australian study [53] compared oral clozapine typical antipsychotics for people with TRS and found the incremental cost-effectiveness ratio (ICER) of clozapine ranges from \$3,000 to 42,000 per DALY, which is below the willingness-to-pay (WTP) threshold set by the authors (\$50,000 per DALY). The South Korea study [80] assessed four oral antipsychotics: olanzapine, risperidone, sertindole and quetiapine, and	For patients with TRS, clozapine is more cost-effective compared to typical antipsychotics. However, the relative cost-effectiveness between clozapine and other atypical antipsychotics (e.g. risperidone) is unknown. Therefore, it is not clear which is the most cost-effective antipsychotic.

Target population	Number of studies	Countries	Study quality	Summary of results	Conclusion
				found that risperidone dominates the other three antipsychotics. The UK study [20] showed that clozapine dominates both electroconvulsive therapy (ECT) and chlorpromazine/ haloperidol strategy.	
<b>Schizophrenia patients who are experiencing adverse events of typical</b>	1	Australia (1/1, 100.0%) [53]	Very serious limitations (1/1, 100.0%) [53]	The most cost-effective antipsychotic reported by the Australian study [53] is oral risperidone (1/1, 100.0%) .	For schizophrenia patients who are experiencing adverse events of typical antipsychotics, oral risperidone is more cost-effective compared to oral olanzapine or oral typical antipsychotics.
<b>Patients with negative symptoms of schizophrenia</b>	1	Hungary (1/1, 100.0%) [81]	Very serious limitations (1/1, 100.0%) [81]	The Hungarian study [81] reported that the ICER of oral cariprazine is € 28,897 per QALY compared to oral risperidone, which is below the WTP threshold set by the authors (€ 34,764 per QALY)	For patients with negative symptoms of schizophrenia, oral cariprazine is more cost-effective than oral risperidone.
<b>2. Different coverage of Medicare drug plans</b>					
<b>General patient with schizophrenia</b>	1	US (1/1, 100.0%) [19]	Very serious limitations (1/1, 100.0%) [19]	The US study [19] compared two strategies: (1) ‘Generic-only coverage’ (Medicare covers cost for generic antipsychotics); (2) ‘No	It is cost-effective for Medicare to cover cost of generic antipsychotics for general

Target population	Number of studies	Countries	Study quality	Summary of results	Conclusion
				coverage' (Medicare does not cover cost of antipsychotic). This study found that 'generic-only coverage' dominates 'no gap coverage'.	schizophrenia patients, compared to no coverage.
<b>3. Electroconvulsive therapy (ECT) versus antipsychotic</b>					
<b>Patients with TRS</b>	1	UK (1/1, 100.0%) [20]	Potentially serious limitations (1/1, 100.0%) [20]	The UK study [20] showed that for patients with TRS who respond to, and can tolerate clozapine, clozapine dominates ECT and chlorpromazine/ haloperidol strategy. For patients with TRS who do not respond to, or who cannot tolerate clozapine, ECT dominates chlorpromazine/ haloperidol strategy.	For adult patients with TRS who respond to, and who can tolerate clozapine, clozapine is more cost-effective compared to ECT and typical antipsychotics. For adult patients with TRS who do not respond to, or who cannot tolerate clozapine, ECT is the more cost-effective compared to typical antipsychotics.
<b>4. Precision medicine test versus no test</b>					
<b>Stable patients with schizophrenia who failed a first-line antipsychotic</b>	1	UK (1/1, 100.0%) [23]	Potentially serious limitations (1/1, 100.0%) [23]	The UK study [23] found that use of a stratified medicine algorithm with a stratifier with 60% sensitivity and specificity in	For stable patients with schizophrenia who failed a first-line antipsychotic, use of a stratified test with 60% sensitivity

<b>Target population</b>	<b>Number of studies</b>	<b>Countries</b>	<b>Study quality</b>	<b>Summary of results</b>	<b>Conclusion</b>
				identifying patients who respond to a 2nd line non-clozapine antipsychotic dominates treatment as usual (no stratified test).	and specificity in identifying patients who respond to a 2nd line non-clozapine antipsychotic is more cost-effective than no test.
<b>Schizophrenia patients in an acute psychotic episode</b>	1	US (1/1, 100.0%) [21]	Very serious limitations (1/1, 100.0%) [21]	The US study [21] compared three strategies: (1) no test, use clozapine as the first-line treatment; (2) no test, use clozapine as the third-line treatment; (3) use test (sensitivity 96%, specificity 38%), use clozapine for patients with positive results. The results showed that Strategy 3 (use test) was dominated by Strategy 1 (no test, clozapine first-line treatment). Compared to Strategy 2 (no test, clozapine first-line treatment), the ICER of Strategy 1 is \$47,705 per QALY.	For schizophrenia patients, a stratified test with 96% sensitivity and 38% specificity for identifying clozapine responders may not be cost-effective compared to no test.
<b>Patients with first episode psychosis (FEP)</b>	1	UK (1/1, 100.0%) [22]	Very serious limitations (1/1, 100.0%) [22]	The UK study [22] compared two strategies of dosing risperidone: (1) 'traditional dosing' (all patients receiving the same dose); (2) 'patient stratification' (dosing is	For patients with FEP who require risperidone, it is cost-effective to use a stratified test with 100% accuracy to

Target population	Number of studies	Countries	Study quality	Summary of results	Conclusion
				individualised for each patient based on the results of a test assuming 100% accuracy). This study found that the ICER of ‘patient stratification’ is £19,252 per QALY.	inform the starting dose compared to no test.
<b>Adult patients with TRS who were taking clozapine</b>	1	US (1/1, 100.0%) [24]	Very serious limitations (1/1, 100.0%) [24]	This US study [24] compared three strategies: (1) current US absolute neutrophil count monitoring (ANCM) schemes; (2) human leukocyte antigen (HLA) genotyping followed by clozapine, with ANCM only for patients who tested positive for one or both alleles (genotype-guided blood sampling); (3) HLA genotyping followed by clozapine for low-risk patients and alternative antipsychotics for patients who tested positive (clozapine substitution scheme). This study found that Strategy 3 was dominated. Compared to Strategy 2, the ICER of Strategy 1 is \$3.93 million per QALY, which is above	For adult patients with TRS who were taking clozapine, the most cost-effective strategy is to use HLA genotyping followed by clozapine, with ANCM only for patients who tested positive for one or both alleles.

Target population	Number of studies	Countries	Study quality	Summary of results	Conclusion
				the WTP threshold set by the authors (US dollars \$50,000 per QALY).	
<b>5. Different monitoring schedules for patients on clozapine</b>					
<b>Patients with TRS on clozapine</b>	1	Switzerland (1/1, 100.0%) [25]	Very serious limitations (1/1, 100.0%) [25]	The Swedish study [25] compared four strategies for monitoring white blood cell count with no monitoring, and found that the ICERs of all four monitoring strategies were at least US\$970,000 per QALY.	For patients with TRS on clozapine, no monitoring is more cost-effective strategy compared to monitoring.
<b>6. Antipsychotic versus antipsychotic plus psychosocial interventions</b>					
<b>All schizophrenia patients</b>	5	Chile, Nigeria and Sri Lanka (1/5, 20.0%) [30], Vietnam (1/5, 20.0%) [26], Spain (1/5, 20.0%) [27], Sub-Saharan Africa and South East Asia countries (1/5, 20.0%) [29], and Thailand (1/5, 20.0%) [28].	Very serious limitations (5/5, 100.0%) [26-30]	Of these three studies, the Vitamin [26] and the Spanish study [27] found that antipsychotics plus psychosocial intervention dominates antipsychotics alone, while the Thailand study [28] found that compared to antipsychotics alone, use of antipsychotics plus psychosocial intervention results in an ICER of 1,900 baht per DALY, which is below the WTP threshold set by the authors (110,000 baht per DALY). The two studies	For general schizophrenia patients, antipsychotic plus psychosocial interventions is more cost-effective than antipsychotic alone.

Target population	Number of studies	Countries	Study quality	Summary of results	Conclusion
				<p>conducted in Chile, Nigeria and Sri Lanka [30] and Sub-Saharan Africa and South East Asia countries (1/5, 20.0%) [29] compared the current situation with typical antipsychotic drug alone, atypical antipsychotic drug alone, typical antipsychotic drug with psychosocial treatment and atypical antipsychotic drug with psychosocial treatment. Both studies found typical antipsychotic drug with psychosocial treatment to be most cost-effective at a WTP threshold of International dollars \$2,000 per DALY averted.</p>	
<b>7. CBT versus no CBT</b>					
Patients with ultra-high risk of developing psychosis or with FEP	1	Netherland (1/1, 100.0%) [17]	Minor limitations (1/1, 100.0%) [17]	The Netherlandish study [17] reported that care as usual plus CBT dominates care as usual.	For patients with ultra-high risk of developing psychosis or with FEP, care as usual plus CBT is more cost-effective than care as usual.
<b>8. Improving access to psychological therapies</b>					

<b>Target population</b>	<b>Number of studies</b>	<b>Countries</b>	<b>Study quality</b>	<b>Summary of results</b>	<b>Conclusion</b>
Patients with psychosis or bipolar disorder	1	UK (1/1, 100.0%) [18]	Very serious limitations (1/1, 100.0%) [18]	The UK study [18] found that compared to the current practice, use of the Improving Access to Psychological Therapies Programme resulted in an ICER of £12.9 per WSAS (Work and Social Adjustment Scale) point.	For patients with psychosis or bipolar disorder, improving their access to psychological therapies may be cost-effective compared to current practice.
<b>9. Employment intervention</b>					
Adults with psychosis and schizophrenia actively seeking employment	1	UK (1/1, 100.0%) [1]	Potentially serious limitations (1/1, 100.0%) [1]	The UK study [1] found that compared to treatment as usual, use of the supported employment programme is associated with an ICER of £5,723 per QALY, which is below the WTP threshold set by the authors (£20,000-30,000 per QALY).	For adults with psychosis and schizophrenia actively seeking employment, supported employment programme is more cost-effective compared to treatment as usual.
<b>10. Different modes of liaison between primary and secondary care service</b>					
<b>People with possible psychotic symptoms</b>	1	UK (1/1, 100.0%) [15]	Potentially serious limitations (1/1, 100.0%) [15]	The UK study [15] compared different intensity of liaison between primary and secondary care for identifying people at clinical high risk of psychosis and with FEP. This study found that the high intensity	For people with early signs of psychosis, it is cost-effective to use intensive intervention to improve liaison between primary and secondary care, compared

Target population	Number of studies	Countries	Study quality	Summary of results	Conclusion
				intervention dominates practice as usual and low-intensity intervention.	to less-intensive intervention or no intervention.

**Abbreviation:**

DALY: disability-adjusted life year; LAI: long acting injection; QALY: quality-adjusted life year; WTP: willingness-to-pay.

### *3.4.1 Conclusions for antipsychotics*

Owing to considerable variability in the number and type of antipsychotics assessed, as well as inconsistent conclusions reported by different studies, it was not possible to identify the most cost-effective antipsychotic for the following patient groups: schizophrenia patients in an acute episode, in remission, or with unspecified psychotic status; schizophrenia patients who have a history of non-adherence; and patients with TRS. For schizophrenia patients who are experiencing adverse events of typical antipsychotics, one study found oral risperidone to be cost-effective compared to oral olanzapine or oral typical antipsychotics [53]. For patients with negative symptoms of schizophrenia, one study found oral cariprazine is more cost-effective than oral risperidone [81].

Of the 57 identified antipsychotic models, 45 reported potential conflicts of interest (the study was funded by, or affiliated with, commercial companies). All 45 studies reported positive findings for the antipsychotic manufactured by the sponsoring commercial company, which indicates that the conclusions of these 45 models might have been influenced by conflicts of interest. Focusing on the 12 studies which did not report potential conflicts of interest, the relative cost-effectiveness of the two most frequently assessed antipsychotics – oral olanzapine and oral risperidone – was explored in order to assess the consistency of conclusions across studies. The results, reported in Table 3, show that for all three patient groups for whom data were available, the studies with no conflicts of interest reported inconsistent conclusions. For example, for studies which focused on schizophrenia patients in remission, two studies found oral risperidone was cost-effective compared to oral olanzapine [1, 31], while three studies found oral olanzapine was cost-effective compared to oral risperidone [42, 47, 50].

**Table 3 Consistency of cost-effectiveness conclusions reported by studies of antipsychotics with no conflicts of interest**

Conclusion	Number of studies	References
<b>support the conclusion</b>		
<b><i>General adult schizophrenia patients (psychotic status unspecified)</i></b>		
Oral risperidone is cost-effective compared to oral olanzapine	1	[53]
Oral olanzapine is cost-effective compared to oral risperidone	1	[75]
<b><i>Schizophrenia patients in an acute episode</i></b>		
Oral risperidone is cost-effective compared to oral olanzapine	1	[40]
Oral olanzapine is cost-effective compared to oral risperidone	1	[37]
<b><i>Schizophrenia patients in remission</i></b>		
Oral risperidone is cost-effective compared to oral olanzapine	2	[1, 31]
Oral olanzapine is cost-effective compared to oral risperidone	3	[42, 47, 50]

### 3.4.2 Conclusions for non-pharmacological interventions

Five models compared the cost-effectiveness of antipsychotic medication alone with antipsychotic medication plus psychosocial interventions [26-30]. All of these studies concluded that antipsychotic medication plus psychosocial interventions was cost-effective compared to antipsychotic medication alone. For the remaining non-pharmacological interventions, each was only assessed by one model. The interventions found to be cost-effective by these models, and the comparators, are as follows:

- a Medicare scheme which covers the cost of generic antipsychotics, compared to no coverage [19];
- clozapine for patients with TRS who respond to, and who can tolerate clozapine, compared to typical antipsychotics and ECT; and ECT for patients with TRS who have not responded to, or who cannot tolerate, clozapine, compared to typical antipsychotics [20];
- a stratified test with 60% sensitivity and 60% specificity for identifying patients who would respond to a second-line non-clozapine antipsychotic after failing a first-line non-clozapine antipsychotic, compared to no stratified test [23];
- a stratified test with 100% accuracy to inform the starting dose of risperidone for patients with first episode psychosis (FEP), compared to no stratified test [22];

- human leukocyte antigen genotyping for identifying patients with TRS who are likely to develop clozapine-induced agranulocytosis, compared to no test [24];
- no monitoring for patients with TRS on clozapine, compared to monitoring [25];
- antipsychotic plus psychosocial interventions for schizophrenia patients, compared to antipsychotic alone [26-30];
- CBT for patients with ultra-high risk of developing psychosis or with FEP, compared to no CBT [17];
- A programme to improve patients' access to psychological therapies, compared to current practice [18];
- supported employment programme for patients with psychosis or schizophrenia actively seeking employment, compared to current practice [1];
- an intensive intervention to improve liaison between primary and secondary care for people with early signs of psychosis, compared to a less-intensive intervention or no intervention [15].

## **4 Discussion**

### **4.1 Summary of findings**

This review of economic models of interventions for schizophrenia found the quality of existing models to be generally low. Common reasons for low-quality included use of a time-horizon which was not sufficiently long, failure to capture the health and cost impact of adverse events of the interventions under assessment, and potential conflicts of interest which may have biased the results of the analyses.

78% of existing models assessed the cost-effectiveness of antipsychotics. However, it was not possible to identify the most cost-effective antipsychotic for the majority of schizophrenia patients due to considerable variation in terms of the number and type of antipsychotics assessed and inconsistent conclusions reported by different studies. Inconsistent findings were a problem for models with conflicts of interest and those where no conflict of interest was identified, which suggests that the variation in results cannot be explained solely by conflicts of interest, but are also likely to be related to differences in choice of treatment options and variances in methods, such as model structure, type of adverse events considered, source of input data and methods of evidence synthesis. The review found very limited or even no economic evidence concerning the prevention, case identification, assessment and diagnosis of psychosis and schizophrenia, as well as non-pharmacological interventions for people with a diagnosis of psychosis or schizophrenia.

## **4.2 Recommendations for future research**

### *4.2.1 Interventions prioritised for future modelling*

A number of interventions for schizophrenia have been recommended in the NICE schizophrenia guideline [1], but have not been formally assessed for cost-effectiveness within a model-based economic evaluation framework. These include: (i) assessment and diagnosis for people with possible psychosis; (ii) interventions to manage challenging behaviour in people with psychosis/schizophrenia; (iii) intervention to promote physical health in people with psychosis/schizophrenia; (iv) peer support or self-management interventions to improve symptoms and functioning for people with psychosis/schizophrenia; and (v) teams and service-level interventions. It is recommended that the above interventions should be prioritised for future economic models.

### *4.2.2 Improvements to the consistency and quality of economic analyses in schizophrenia*

One option for improving the consistency and quality of economic analyses in schizophrenia would involve the development of an agreed ‘generic’ model structure [82], populated using input data obtained from high quality evidence, which would allow for the consistent economic evaluation of new and existing treatment options as and when such analyses are required (e.g. when a new drug comes to market). Provided the basis of the model (e.g. its structure and the evidence used to inform it) can be agreed, the development of a generic schizophrenia model would remove the possibility of producing inconsistent results and improve model quality. Development of a registry of economic models by disease areas is a potential method for promoting use of generic modelling approach [83].

As an extension of generic models, Tappenden *et al.* have proposed the development of Whole Disease Models (WDMs) – these are generic models which, in principle, allow for the consistent economic analysis of any individual or combination of options at any point in the disease and treatment pathway [84]. This “whole system” approach would provide a single platform for the economic evaluation of all key interventions for schizophrenia based on a common set of assumptions and input data across the whole care pathway. Whilst this type of modelling approach represents a significant undertaking in terms of model development time and resource, it would provide a means of addressing the significant gaps identified within this review relating to the inconsistent and/or absent economic evidence for current treatments for schizophrenia. In addition, it may be particularly valuable in capturing interactions between interventions given at different points of the pathway, for

example, interventions which reduce a patient's duration of untreated psychosis earlier in the pathway are likely to impact upon the cost-effectiveness of other treatments later on in the pathway.

### **4.3 Strengths & Limitations**

#### *4.3.1 Strengths*

Whilst a number of systematic reviews have been identified that assess economic studies for schizophrenia, most of them focused on cost-effectiveness of antipsychotics and ignored other non-pharmacological interventions [1, 85-87]. Before our study, there is only one review (Németh *et al.*[88]) which includes all model-based economic evaluation for schizophrenia regardless of which intervention was assessed. However, Németh *et al.* only searched one electronic database (MEDLINE); in addition, it focused on the methods used by published models such as utility mapping algorithms, without reporting conclusions of the identified models. To our knowledge, our study presents the first systematic review which summarises the cost-effectiveness evidence reported by existing model-based economic analyses which covers the entire schizophrenia care pathway, including any intervention for the prevention, detection, diagnosis, treatment and follow-up of schizophrenia. The information reported by this systematic review can be used to help researchers, commissioners or other stakeholders to rapidly locate relevant economic evidence that they are interested in, critically appraise existing model-based economic analyses, and make resource allocation decisions based on current model-based economic analyses. Recommendations for future research can be used to fill the evidence gap and improve the applicability and quality of future models for schizophrenia.

#### *4.3.2 Limitations*

This review is subject to two main limitations. Firstly, this review only included model-based economic evaluations. Economic evaluations based on other analytic frameworks, such as clinical trials, cohort studies and database studies, which represent a significant proportion of economic evidence, were excluded from this review. Economic analyses undertaken alongside clinical trials without extrapolation or the use of external evidence can also be a useful source of economic evidence; however, they do not always provide a sufficient basis for decision-making. For example, a single trial might not compare all the available options, provide evidence on all relevant inputs, or be conducted over a long enough period of time to capture differences in important economic or clinical outcomes. Therefore, a review of model-based economic evaluations was considered to be most relevant for decision-makers who are interested in resource allocation decisions across the

entire schizophrenia pathway. Secondly, this review only included models published after 2005. This is because studies published before that time were deemed to have limited relevance to current practice due to the rapidly changing nature of treatments, health services and methods of economic evaluation.

## **5 Conclusion**

This review highlights a lack of models for non-pharmacological interventions for schizophrenia, and limitations of existing models, including low quality and inconsistency in conclusions. A consistent basis for the model structure, use of evidence and assumptions in health economic models is required, in order to improve the consistency and quality of future health economic models for the economic evaluation of interventions for schizophrenia. This consistency could be applied using ‘generic’ models, which might include a *de novo* WDM.

## **Author Contributions**

HJ conducted the systematic review and led the writing of the paper. EA performed 1st round (title and abstract) screening and 2nd round (full-text) sifting as the second reviewer for the original search (22<sup>nd</sup> June 2015) and first update search (4<sup>th</sup> March 2018). DA performed 1st round screening and 2nd round sifting as the second reviewer for the second update search (21<sup>st</sup> Jan 2020). PT, SR, JM and SB advised on the overall plan and implementation of the systematic review. HJ wrote the first draft of the paper, which was subsequently been edited by all authors who have approved the final version. HJ will serve as a guarantor for the overall content of the manuscript.

## **Compliance with Ethical Standards**

**Data Availability Statement** All data generated or analysed during this study are included in this published article.

**Funding** No funding was received for the preparation of this study.

**Conflict of interest** JM received grants from HS Lundbeck outside this submitted review. HJ, PT, SR, EA, DA and SB declare no conflicts of interest.

## Reference

1. National Collaborating Centre for Mental Health. Psychosis and schizophrenia in adults: prevention and management. NICE guideline (CG178). London, UK: The British Psychological Society and The Royal College of Psychiatrists; 2014.
2. NHS England. Report of the early intervention in psychosis audit. London, UK: NHS England; 2016.
3. Patel V, Saxena S, Lund C, Thornicroft G, Baingana F, Bolton P, et al. The Lancet Commission on global mental health and sustainable development. *Lancet*. 2018 Oct 27;392(10157):1553-98.
4. Centre for Economic Performance's Mental Health Policy Group. How mental illness loses out in the NHS. London, UK: London School of Economics and Political Science; 2012.
5. Caro JJ, Briggs AH, Siebert U, Kuntz KM. Modeling Good Research Practices—Overview: A report of the ISPOR-SMDM Modeling Good Research Practices Task Force-1. *Medical Decision Making*. 2012 Sep-Oct;32(5):667-77.
6. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLoS medicine*. 2009;6(7):1-6.
7. Drummond M, F., Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. *British Medical Journal*. 1996;313:275-83.
8. Evers S, Goossens M, De Vet H, Van Tulder M, Ament A. Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria. *International Journal of Technology Assessment in Health Care*. 2005;21(2):240-5.
9. Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement. *European Journal of Health Economics*. 2013;14(3):367-72.
10. Cooper N, Coyle D, Abrams K, Mugford M, Sutton A. Use of evidence in decision models: An appraisal of health technology assessments in the UK since 1997. *Journal of Health Services Research and Policy*. 2005;10(4):245-50.
11. National Institute for Health and Care Excellence. Developing NICE guidelines: the manual. London, UK: National Institute for Health and Care Excellence; 2014.
12. Philips Z, Ginnelly L, Sculpher M, Claxton K, Golder S, Riemsma R, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. *Health Technology Assessment*. 2004;8(36):iii-61.
13. Ungar WJ, Santos MT. The pediatric quality appraisal questionnaire: An instrument for evaluation of the pediatric health economics literature. *Value in Health*. 2003;6(5):584-94.
14. Shuster JJ. Review of Cochrane handbook for systematic reviews for interventions, Version 5.1.0. *Research Synthesis Methods*. 2011;2(2):126-30.
15. Perez J, Jin H, Russo DA, Stochl J, Painter M, Shelley G, et al. Clinical effectiveness and cost-effectiveness of tailored intensive liaison between primary and secondary care to identify individuals at risk of a first psychotic illness (the LEGs study): a cluster-randomised controlled trial. *The Lancet Psychiatry*. 2015;2(11):984-93.
16. Heeg B, Buskens E, Botteman M, Caleo S, Ingham M, Damen J, et al. The cost-effectiveness of atypicals in the UK. *Value in Health*. 2008 Dec;11(7):1007-21.
17. Wijnen BFM, Thielen FW, Konings S, Feenstra T, Van Der Gaag M, Veling W, et al. Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis. Expert review of pharmacoeconomics & outcomes research. 2019:1-11.
18. Zala D, Brabban A, Stirzaker A, Kartha MR, McCrone P. The Cost-Effectiveness of the Improving Access to Psychological Therapies (IAPT) Programme in Severe Mental Illness: A Decision Analytical Model Using Routine Data. *Community mental health journal*. 2019;55(5):873-83.
19. Smith KJ, Baik SH, Reynolds CF, 3rd, Rollman BL, Zhang Y. Cost-effectiveness of Medicare drug plans in schizophrenia and bipolar disorder. *American Journal of Managed Care*. 2013;19(2).

20. Greenhalgh J, Knight C, Hind D, Beverley C, Walters S. Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: Systematic reviews and economic modelling studies. *Health Technology Assessment*. 2005 March;9(9):iii-94.
21. Perlis RH, Ganz DA, Avorn J, Schneeweiss S, Glynn RJ, Smoller JW, et al. Pharmacogenetic Testing in the Clinical Management of Schizophrenia: A Decision-Analytic Model. *Journal of Clinical Psychopharmacology*. 2005 Oct;25(5):427-34.
22. Rejon-Parrilla JC, Nuijten M, Redekop WK, Gaultney JG. Economic evaluation of the use of a pharmacogenetic diagnostic test in schizophrenia. *Health Policy and Technology*. 2014 01 Dec;3(4):314-24.
23. Jin H, McCrone P, MacCabe JH. Stratified medicine in schizophrenia: how accurate would a test of drug response need to be to achieve cost-effective improvements in quality of life? *European Journal of Health Economics*. 2019;20(9):1425-35.
24. Girardin FR, Poncet A, Perrier A, Vernaz N, Pletscher M, C FS, et al. Cost-effectiveness of HLA-DQB1/HLA-B pharmacogenetic-guided treatment and blood monitoring in US patients taking clozapine. *Pharmacogenomics Journal*. 2019;19(2):211-8.
25. Girardin FR, Poncet A, Blondon M, Rollason V, Vernaz N, Chalandon Y, et al. Monitoring white blood cell count in adult patients with schizophrenia who are taking clozapine: A cost-effectiveness analysis. *The Lancet Psychiatry*. 2014 01 Jun;1(1):55-62.
26. Anh NQ, Linh BN, Ha NT, Phanthunane P, Huong NT. Schizophrenia interventions in Vietnam: Primary results from a cost-effectiveness study. *Global Public Health: An International Journal for Research, Policy and Practice*. 2015 Feb;10(Suppl 1):S21-S39.
27. Gutierrez-Recacha P, Chisholm D, Haro JM, Salvador-Carulla L, Ayuso-Mateos JL. Cost-effectiveness of different clinical interventions for reducing the burden of schizophrenia in Spain. *Acta Psychiatrica Scandinavica*. 2006;114(Supplement 432):29-38.
28. Phanthunane P, Vos T, Whiteford H, Bertram M. Cost-effectiveness of pharmacological and psychosocial interventions for schizophrenia. *Cost Eff Resour Alloc*. 2011;9:6.
29. Chisholm D, Saxena S. Cost effectiveness of strategies to combat neuropsychiatric conditions in sub-Saharan Africa and South East Asia: mathematical modelling study. *Bmj*. 2012;344:e609.
30. Chisholm D, Gureje O, Saldivia S, Calderon MV, Wickremasinghe R, Mendis N, et al. Schizophrenia treatment in the developing world: An interregional and multinational cost-effectiveness analysis. *Bulletin of the World Health Organization*. 2008 July;86(7):542-51.
31. Lin L, Zhao YJ, Zhou HJ, Khoo AL, Teng M, Soh LB, et al. Comparative cost-effectiveness of 11 oral antipsychotics for relapse prevention in schizophrenia within Singapore using effectiveness estimates from a network meta-analysis. *International Clinical Psychopharmacology*. 2016 28 Jan;31(2):84-92.
32. Rajagopalan K, Trueman D, Crowe L, Squirrell D, Loebel A. Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia. *PharmacoEconomics*. 2016 01 Jul;34(7):709-21.
33. Pribylova L, Kolek M, Vesela S, Duba J, Slesinger J, Doleckova J. De novo cost-utility analysis of oral paliperidone in the treatment of schizoaffective disorder. *Journal of Psychiatric Research*. 2015 November;70:33-7.
34. Beard AM, Maciver F, Clouth J, Ruther E. A decision model to compare health care costs of olanzapine and risperidone treatment of schizophrenia in Germany. *European Journal of Health Economics*. 2006;7:165-72.
35. Geitona M, Kousoulakou H, Ollandezos M, Athanasakis K, Papanicolaou S, Kyriopoulos I. Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study. *Annals of General Psychiatry*. 2008;7:16.
36. Mould-Quevedo J, Contreras-Hernandez I, Verduzco W, Mejia-Arangure JM, Garduno-Espinosa J. Cost-effectiveness simulation analysis of schizophrenia at the Instituto Mexicano del Seguro Social: Assessment of typical and atypical antipsychotics. *Rev*. 2009 Jul;2(3):108-18.

37. Kim K, Aas E. Cost-effectiveness analysis of olanzapine and risperidone in Norway. *J Ment Health Policy Econ*. 2011 Sep;14(3):125-35.
38. Treur M, Baca E, Bobes J, Canas F, Salvador L, Gonzalez B, et al. The cost-effectiveness of paliperidone extended release in Spain. *Journal of Medical Economics*. 2012;15 Suppl 1:26-34.
39. Lindstrom E, Eberhard J, Fors BM, Hansen K, Sapin C. A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden. *Nordic Journal of Psychiatry*. 2011 Dec;65(6):403-13.
40. Bounthavong M, Okamoto MP. Decision analysis model evaluating the cost-effectiveness of risperidone, olanzapine and haloperidol in the treatment of schizophrenia. *Journal of Evaluation in Clinical Practice*. 2007 Jun;13(3):453-60.
41. Ascher-Svanum H, Furiak NM, Lawson AH, Klein TM, Smolen LJ, Conley RR, et al. Cost-effectiveness of several atypical antipsychotics in orally disintegrating tablets compared with standard oral tablets in the treatment of schizophrenia in the United States. *Journal of Medical Economics*. 2012;15(3):531-47.
42. Park T, Kuntz KM. Cost-effectiveness of second-generation antipsychotics for the treatment of schizophrenia. *Value in Health*. 2014 Jun;17(4):310-9.
43. Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Conley RR, et al. Cost-effectiveness model comparing olanzapine and other oral atypical antipsychotics in the treatment of schizophrenia in the United States. *Cost Eff Resour Alloc*. 2009;7:4.
44. Aigbogun MS, Liu S, Kamat SA, Sapin C, Duhig AM, Citrome L. Relapse prevention: A cost-effectiveness analysis of brexpiprazole treatment in adult patients with schizophrenia in the USA. *ClinicoEconomics and Outcomes Research*. 2018;10:443-56.
45. Bernardo M, Ramon Azanza J, Rubio-Terres C, Rejas J. Cost-effectiveness analysis of schizophrenia relapse prevention : an economic evaluation of the ZEUS (Ziprasidone-Extended-Use-In-Schizophrenia) study in Spain. *Clinical Drug Investigation*. 2006;26(8):447-57.
46. Garcia-Ruiz AJ, Perez-Costillas L, Montesinos AC, Alcalde J, Oyaguez I, Casado MA. Cost-effectiveness analysis of antipsychotics in reducing schizophrenia relapses. *Health Economics Review*. 2012;2(1):8.
47. Lindner LM, Marasciulo AC, Farias MR, Grohs GE. Economic evaluation of antipsychotic drugs for schizophrenia treatment within the Brazilian Healthcare System. *Revista de Saude Publica*. 2009 Aug;43 Suppl 1:62-9.
48. Zhao J, Jiang K, Li Q, Zhang Y, Cheng Y, Lin Z, et al. Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China. *Journal of medical economics*. 2019;22(5):439-46.
49. Thavornwattanayong W, Lertsirimunkong J, Thongkerd N, Pitakthanin N, Wettayanon P, Pongjakpanit H. Cost-effectiveness analysis of aripiprazole compared with risperidone in the treatment of acute schizophrenia patients in Thailand. *Thai Journal of Pharmaceutical Sciences*. 2018;42(3):169-75.
50. Lubinga SJ, Mutamba BB, Nganizi A, Babigumira JB. A Cost-effectiveness Analysis of Antipsychotics for Treatment of Schizophrenia in Uganda. *Applied Health Economics and Health Policy*. 2015 10 May;13(5):493-506.
51. Lachaine J, Beauchemin C, Mathurin K, Gilbert D, Beillat M. Cost-effectiveness of asenapine in the treatment of schizophrenia in Canada. *Journal of Medical Economics*. 2014 Apr;17(4):296-304.
52. McIntyre RS, Cragin L, Sorensen S, Naci H, Baker T, Roussy J-P. Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia using ziprasidone, olanzapine, quetiapine and risperidone in Canada: A cost-effectiveness analysis. *Journal of Evaluation in Clinical Practice*. 2010 Aug;16(4):744-55.
53. Magnus A, Carr V, Mihalopoulos C, Carter R, Vos T. Assessing cost-effectiveness of drug interventions for schizophrenia. *Australian and New Zealand Journal of Psychiatry*. 2005;39(1-2):44-54.

54. Treur M, Heeg B, Moller HJ, Schmeding A, van Hout B. A pharmaco-economic analysis of patients with schizophrenia switching to generic risperidone involving a possible compliance loss. *BMC Health Services Research*. 2009;9:32.
55. Kasteng F, Eriksson J, Sennfalt K, Lindgren P. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder. *Acta Psychiatrica Scandinavica*. 2011 Sep;124(3):214-25.
56. Einarson TR, Pudas H, Zilbershtein R, Jensen R, Vicente C, Piwko C, et al. Cost-effectiveness analysis of atypical long-acting antipsychotics for treating chronic schizophrenia in Finland. *Journal of Medical Economics*. 2013 September;16(9):1096-105.
57. Einarson TR, Pudas H, Goswami P, Van Impe K, Bereza BG. Pharmacoeconomics of long-Acting atypical antipsychotics for acutely relapsed chronic schizophrenia in Finland. *Journal of Medical Economics*. 2016 01 Feb;19(2):111-20.
58. Laux G, Heeg B, van Hout BA, Mehnert A. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. *Pharmacoeconomics*. 2005;23 Suppl 1:49-61.
59. Zeidler J, Mahlich J, Greiner W, Heres S. Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany. *Applied Health Economics and Health Policy*. 2013 October 01;11(5):509-21.
60. Einarson TR, Maia-Lopes S, Goswami P, Bereza BG, Van Impe K. Economic analysis of paliperidone long-acting injectable for chronic schizophrenia in Portugal. *Journal of Medical Economics*. 2016 01 Sep;19(9):913-21.
61. Heeg B, Antunes J, Figueira M, Jara J, Teixeira J, Palha A, et al. Cost-effectiveness and budget impact of long-acting risperidone in Portugal: A modeling exercise. *Current Medical Research and Opinion*. 2008;24(2):349-58.
62. Mehnert A, Nicholl D, Pudas H, Martin M, McGuire A. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden. *Journal of Medical Economics*. 2012;15(5):844-61.
63. Hensen M, Heeg B, Lothgren M, van Hout B. Cost effectiveness of long-acting risperidone in Sweden. *Appl Health Econ Health Policy*. 2010;8(5):327-41.
64. Citrome L, Kamat SA, Sapin C, Baker RA, Eramo A, Ortendahl J, et al. Cost-effectiveness of aripiprazole once-monthly compared with paliperidone palmitate once-monthly injectable for the treatment of schizophrenia in the United States. *Journal of Medical Economics*. 2014 Aug;17(8):567-76.
65. Furiak NM, Ascher-Svanum H, Klein RW, Smolen LJ, Lawson AH, Montgomery W, et al. Cost-effectiveness of olanzapine long-acting injection in the treatment of patients with schizophrenia in the United States: a micro-simulation economic decision model. *Curr Med Res Opin*. 2011 Apr;27(4):713-30.
66. De Graeve D, Smet A, Mehnert, Caleo S, Miadi-Fargier H, Mosqueda GJ, et al. Long-acting risperidone compared with oral olanzapine and haloperidol depot in schizophrenia: a Belgian cost-effectiveness analysis. *Pharmacoeconomics*. 2005;23(Supplement 1):35-47.
67. Chue P, Heeg BM, Buskens E, van Hout BA. Modelling the impact of compliance on the costs and effects of long-acting risperidone in Canada. *Pharmacoeconomics*. 2005;23(Suppl 1):62-74.
68. Yang L, Li M, Tao LB, Zhang M, Nicholl MD, Dong P. Cost-effectiveness of long-acting risperidone injection versus alternative atypical antipsychotic agents in patients with schizophrenia in China. *Value in Health*. 2009 Nov-Dec;12 Suppl 3:S66-9.
69. Jukic V, Jakovljevic M, Filipcic I, Herceg M, Silic A, Tomljanovic T, et al. Cost-utility analysis of depot atypical antipsychotics for chronic schizophrenia in Croatia 2013.
70. Einarson TR, Zilbershtein R, Skoupa J, Vesela S, Garg M, Hemels ME. Economic and clinical comparison of atypical depot antipsychotic drugs for treatment of chronic schizophrenia in the Czech Republic. *Journal of Medical Economics*. 2013 Sep;16(9):1089-95.

71. Druais S, Doutriaux A, Cognet M, Godet A, Lancon C, Levy P, et al. Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France. *Pharmacoeconomics*. 2016 01 Apr;34(4):363-91.
72. Einarson TR, Geitona M, Chaidemenos A, Karpouza V, Mougiakos T, Paterakis P, et al. Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece. *Annals of General Psychiatry*. 2012;11(1):18.
73. Einarson TR, Bereza BG, Tedouri F, Van Impe K, Denee TR, Dries PJT. Cost-effectiveness of 3-month paliperidone therapy for chronic schizophrenia in the Netherlands. *Journal of Medical Economics*. 2017 02 Nov;20(11):1187-99.
74. Einarson TR, Vicente C, Zilbershtein R, Piwko C, Bo CN, Pudas H, et al. Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway. *Acta Neuropsychiatrica*. 2013 Apr;25(2):85-94.
75. Obradovic M, Mrhar A, Kos M. Cost-effectiveness of antipsychotics for outpatients with chronic schizophrenia. *International Journal of Clinical Practice*. 2007 Dec;61(12):1979-88.
76. Dilla T, Moller J, O'Donohoe P, Alvarez M, Sacristan JA, Happich M, et al. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison. *BMC Psychiatry*. 2014;14(1):298.
77. Yang YK, Tarn YH, Wang TY, Liu CY, Laio YC, Chou YH, et al. Pharmacoeconomic evaluation of schizophrenia in Taiwan: model comparison of long-acting risperidone versus olanzapine versus depot haloperidol based on estimated costs. *Psychiatry and Clinical Neurosciences*. 2005;59(4):385-94.
78. Tempest M, Sapin C, Beillat M, Robinson P, Treur M. Cost-effectiveness analysis of aripiprazole once-monthly for the treatment of schizophrenia in the UK. *Journal of Mental Health Policy and Economics*. 2015;18(4):185-200.
79. Nuhoho S, Saad A, Saumell G, Ribes D, El Khoury AC. Economic evaluation of paliperidone palmitate once monthly for treating chronic schizophrenia patients in the United Arab Emirates. *Current Medical Research and Opinion*. 2018 03 Apr;34(4):601-11.
80. Kim BR, Lee TJ, Lee HJ, Park BH, Yang BM. Cost-effectiveness of sertindole among atypical antipsychotics in the treatment of schizophrenia in South Korea. *Value in Health Regional Issues*. 2012;1(1):59-65.
81. Nemeth B, Bendes R, Nagy B, Gotze A, Koczian K, Horvath M, et al. Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia. *Health Policy and Technology*. 2019;8(1):84-91.
82. Sampson CJ, Arnold R, Bryan S, Clarke P, Ekins S, Hatswell A, et al. Transparency in Decision Modelling: What, Why, Who and How? *Pharmacoeconomics*. 2019 Nov;37(11):1355-69.
83. Kent S, Becker F, Feenstra T, Tran-Duy A, Schlackow I, Tew M, et al. The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. *Pharmacoeconomics*. 2019 2019/11/01;37(11):1305-12.
84. Tappenden P, Chilcott J, Brennan A, Squires H, Stevenson M. Whole Disease Modeling to Inform Resource Allocation Decisions in Cancer: A Methodological Framework. *Value in Health*. 2012 12//;15(8):1127-36.
85. Achilla E, McCrone P. The cost effectiveness of long-acting/extended-release antipsychotics for the treatment of schizophrenia: A systematic review of economic evaluations. *Applied health economics and health policy*. 2013:95-106.
86. von Scheele B, Mauskopf J, Brodtkorb TH, Ainsworth C, Berardo CG, Patel A. Relationship between modeling technique and reported outcomes: case studies in models for the treatment of schizophrenia. *Expert Review of Pharmacoeconomics & Outcomes Research*. 2014 Apr;14(2):235-57.
87. Zhou J, Millier A, Toumi M. Systematic review of pharmacoeconomic models for schizophrenia. *Journal of market access & health policy*. 2018;6(1):1508272.

88. Nemeth B, Fasseeh A, Molnar A, Bitter I, Horvath M, Koczian K, et al. A systematic review of health economic models and utility estimation methods in schizophrenia. *Expert Rev Pharmacoecon Outcomes Res.* 2018 Jun;18(3):267-75.